179 related articles for article (PubMed ID: 26153330)
21. The landscape of EGFR pathways and personalized management of non-small-cell lung cancer.
Cheng L; Zhang S; Alexander R; Yao Y; MacLennan GT; Pan CX; Huang J; Wang M; Montironi R; Lopez-Beltran A
Future Oncol; 2011 Apr; 7(4):519-41. PubMed ID: 21463141
[TBL] [Abstract][Full Text] [Related]
22. Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience.
Son C; Kang EJ; Roh MS
Diagn Cytopathol; 2015 Jul; 43(7):532-8. PubMed ID: 25427228
[TBL] [Abstract][Full Text] [Related]
23. Detection of rearrangements and transcriptional up-regulation of ALK in FFPE lung cancer specimens using a novel, sensitive, quantitative reverse transcription polymerase chain reaction assay.
Gruber K; Horn H; Kalla J; Fritz P; Rosenwald A; Kohlhäufl M; Friedel G; Schwab M; Ott G; Kalla C
J Thorac Oncol; 2014 Mar; 9(3):307-15. PubMed ID: 24495999
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and accuracy of molecular testing in specimens obtained with small biopsy forceps: comparison with the results of surgical specimens.
Oki M; Yatabe Y; Saka H; Kitagawa C; Kogure Y; Ichihara S; Moritani S
Respiration; 2015; 89(3):235-42. PubMed ID: 25676841
[TBL] [Abstract][Full Text] [Related]
26. MET: a new promising biomarker in non-small-cell lung carcinoma.
Pérez-Ramírez C; Cañadas-Garre M; Jiménez-Varo E; Faus-Dáder MJ; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(6):631-47. PubMed ID: 25893986
[TBL] [Abstract][Full Text] [Related]
27. Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options.
Lazzari C; Spitaleri G; Catania C; Barberis M; Noberasco C; Santarpia M; Delmonte A; Toffalorio F; Conforti F; De Pas TM
Crit Rev Oncol Hematol; 2014 Mar; 89(3):358-65. PubMed ID: 24156959
[TBL] [Abstract][Full Text] [Related]
28. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma.
Ileana EE; Wistuba II; Izzo JG
Cancer J; 2015; 21(5):413-24. PubMed ID: 26389767
[TBL] [Abstract][Full Text] [Related]
29. Treatment and detection of ALK-rearranged NSCLC.
Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
[TBL] [Abstract][Full Text] [Related]
30. EGFR mutational genotyping of liquid based cytology samples obtained via fine needle aspiration (FNA) at endobronchial ultrasound of non-small cell lung cancer (NSCLC).
Reynolds JP; Tubbs RR; Minca EC; MacNamara S; Almeida FA; Ma PC; Pennell NA; Cicenia JC
Lung Cancer; 2014 Nov; 86(2):158-63. PubMed ID: 25263855
[TBL] [Abstract][Full Text] [Related]
31. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
[TBL] [Abstract][Full Text] [Related]
32. Weighing tumor biology in treatment decisions for patients with non-small cell lung cancer.
Shepherd FA; Rosell R
J Thorac Oncol; 2007 Jun; 2 Suppl 2():S68-76. PubMed ID: 17589302
[TBL] [Abstract][Full Text] [Related]
33. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
[TBL] [Abstract][Full Text] [Related]
34. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
Weber B; Hager H; Sorensen BS; McCulloch T; Mellemgaard A; Khalil AA; Nexo E; Meldgaard P
Lung Cancer; 2014 Feb; 83(2):224-30. PubMed ID: 24388704
[TBL] [Abstract][Full Text] [Related]
35. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
36. Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.
Levy BP; Chioda MD; Herndon D; Longshore JW; Mohamed M; Ou SH; Reynolds C; Singh J; Wistuba II; Bunn PA; Hirsch FR
Oncologist; 2015 Oct; 20(10):1175-81. PubMed ID: 26330460
[TBL] [Abstract][Full Text] [Related]
37. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
Klempner SJ; Ou SH
Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
[TBL] [Abstract][Full Text] [Related]
38. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
John T; Liu G; Tsao MS
Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
[TBL] [Abstract][Full Text] [Related]
39. Predictive markers in the adjuvant therapy of non-small cell lung cancer.
Filipits M; Pirker R
Lung Cancer; 2011 Dec; 74(3):355-63. PubMed ID: 21885151
[TBL] [Abstract][Full Text] [Related]
40. New targets in advanced NSCLC: EML4-ALK.
Crystal AS; Shaw AT
Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
